Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12294290 | 0.80 | ATM (0.43) | KDM4EALDH1A1GAA | |
| SCHEMBL2559112 | 0.79 | NPC1 (0.43) | KDM4EALDH1A1POLBGAA | |
| SCHEMBL646539 | 0.77 | DPP4 (0.47) | DPP4DPP7IDH1IRAK4GSK3B | |
| SCHEMBL12286723 | 0.77 | CHEK1 (0.32) | — | |
| SCHEMBL2563332 | 0.77 | LOXL2 (0.40) | KDM4EALDH1A1GAA | |
| SCHEMBL2561830 | 0.77 | GPR55 (0.36) | KDM4EALDH1A1GAA | |
| SCHEMBL12294502 | 0.75 | TAAR1 (0.50) | KDM4EALDH1A1GAA | |
| SCHEMBL2563223 | 0.75 | NPY5R (0.38) | KDM4EALDH1A1POLBGAA | |
| SCHEMBL2564435 | 0.74 | NNMT (0.50) | KDM4EALDH1A1VNN1 | |
| SCHEMBL2564060 | 0.74 | GABRG2 (0.42) | ALDH1A1VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200717-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-07-14 | — | — | US | claimed |
| US-9994528-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994528-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994528-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20160200717-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200717-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200717-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2016-07-14 | — | — | US | disclosed |
| EP-2560488-B1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2560488-B1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-9133123-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133123-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133123-B2 | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20130150368-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150368-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150368-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2560488-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | Cytokinetics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011133920-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133920-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | CYTOKINETICS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200717-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | SLC7A1, PRMT5, H1-5 | DPP4 458/4885KDM4E 645/4885ALDH1A1 2669/4885 |
| US-20130150368-A1 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | SLC7A1, PRMT5, H1-5 | DPP4 458/4885KDM4E 645/4885ALDH1A1 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.